StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie synthroid (levothyroxine) [legacy through FY21] — Worldwide net revenues ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues

Latest, FY2021
767
Period ended Dec 31, 2021
Change on a year earlier
-0.5%
771 in FY2020
History
7 years
Since FY2015
Sources
3
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSynthroid (levothyroxine) [legacy through FY21] — Worldwide net revenues ($M) ($M)Year on yearSource
FY2021Dec 31, 2021767-0.5%Form 10-K (filed 2022-02-18) ↗
FY2020Dec 31, 2020771-1.9%Form 10-K (filed 2022-02-18) ↗
FY2019Dec 31, 2019786+1.3%Form 10-K (filed 2022-02-18) ↗
FY2018Dec 31, 2018776-0.6%Form 10-K (filed 2021-02-19) ↗
FY2017Dec 31, 2017781+2.4%Form 10-K (filed 2018-02-16) ↗
FY2016Dec 31, 2016763+1.1%Form 10-K (filed 2018-02-16) ↗
FY2015Dec 31, 2015755–Form 10-K (filed 2018-02-16) ↗

Breakdown

What makes up synthroid (levothyroxine) [legacy through fy21] — worldwide net revenues ($m)

Cite this data

StockData. (2026). AbbVie Synthroid (levothyroxine) [legacy through FY21] — Worldwide net revenues ($M) ($M), annual FY2015–FY2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/synthroid_ww

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.